PE20030646A1 - Medicamentos para la inhalacion que comprenden sales de tiotropio y salmeterol - Google Patents
Medicamentos para la inhalacion que comprenden sales de tiotropio y salmeterolInfo
- Publication number
- PE20030646A1 PE20030646A1 PE2002000899A PE2002000899A PE20030646A1 PE 20030646 A1 PE20030646 A1 PE 20030646A1 PE 2002000899 A PE2002000899 A PE 2002000899A PE 2002000899 A PE2002000899 A PE 2002000899A PE 20030646 A1 PE20030646 A1 PE 20030646A1
- Authority
- PE
- Peru
- Prior art keywords
- salmeterol
- salts
- presentation
- inhalation
- powder
- Prior art date
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229960004017 salmeterol Drugs 0.000 title abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- -1 HYDROXY-DI-2-THENYL-ACETYL Chemical class 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A MEDICAMENTOS PARA INHALACION QUE COMPRENDEN 1)SALES DE TIOTROPIO (1a,2b,5a,7b)-7-[(HIDROXI-DI-2-TIENIL-ACETIL)OXI]-9,9-DIMETIL-3-OXA-9-AZONIA-TRICICLO[3.3.1.0(2,4)]NONANO DE PREFERENCIA CLORURO, BROMURO, YODURO, METANO-SULFONATO, PARA TOLUENO SULFONATO, METIL SULFATO) EN COMBINACION 2)CON SALES DIFICILMENTE SOLUBLES DE SALMETEROL CON UNA SOLUBILIDAD EN AGUA DE 0,1 mg/ml, QUE SE CARACTERIZA POR PRESENTAR ALTA COMPATIBILIDAD LOCAL, SE ENCUENTRAN EN UNA FORMA DE PRESENTACION O EN DOS FORMAS DE PRESENTACION, LAS RELACIONES EN PESO DE TIOTROPIO SE ENCUENTRAN EN EL INTERVALO DE 1:300 A 30:1, SIENDO DE PREFERENCIA UN POLVO PARA INHALACION QUE CONTIENE LOS COMPONENTES EN MEZCLA CON SUSTANCIAS AUXILIARES FISIOLOGICAMENTE INOCUAS COMO MONOSACARIDOS, DISACARIDOS, OLIGOSACARIDOS CON UN TAMANO DE PARTICULAS DE HASTA 250µm, TAMBIEN SE PUEDE PRESENTAR EN CAPSULAS CON UN CONTENIDO DE POLVO (INHALETAS). EL MEDICAMENTO TIENE UN INICIO DEL EFECTO RAPIDO, DURACION DEL EFECTO LARGAMENTE PERSISTENTE Y PUEDE SER UTIL PARA TERAPIA DE ENFERMEDADES DE VIAS RESPIRATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS COMO ASMA, COPD
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001145438 DE10145438A1 (de) | 2001-09-14 | 2001-09-14 | Neue Arzneimittel zur Inhalation |
| DE2002109243 DE10209243A1 (de) | 2002-03-04 | 2002-03-04 | Neue Arzneimittelkombination zur Inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030646A1 true PE20030646A1 (es) | 2003-07-23 |
Family
ID=26010149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000899A PE20030646A1 (es) | 2001-09-14 | 2002-09-12 | Medicamentos para la inhalacion que comprenden sales de tiotropio y salmeterol |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1429768B1 (es) |
| JP (1) | JP2005504076A (es) |
| AR (1) | AR036518A1 (es) |
| CA (1) | CA2459493C (es) |
| MX (1) | MXPA04002401A (es) |
| PE (1) | PE20030646A1 (es) |
| UY (1) | UY27445A1 (es) |
| WO (1) | WO2003024452A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| UA83813C2 (ru) * | 2002-12-20 | 2008-08-26 | Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг | Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола |
| AU2004262902B2 (en) * | 2003-07-29 | 2009-07-30 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic |
| JP2009504603A (ja) * | 2005-08-06 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | チオトロピウム塩とサルメテロールの塩とを組合せて投与する呼吸困難の治療方法 |
| WO2008020032A1 (en) * | 2006-08-16 | 2008-02-21 | Action Medicines, S.L. | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1172663B (de) * | 1961-04-28 | 1964-06-25 | Maggioni & C Spa | Verfahren zur Herstellung von Wismut-tri-(p-phenylcinnamat) |
| GB8310477D0 (en) * | 1983-04-18 | 1983-05-25 | Glaxo Group Ltd | Chemical compounds |
| DE19726871C1 (de) * | 1997-06-24 | 1999-03-04 | Werner Kreutz | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| DE60001492T2 (de) * | 1999-04-14 | 2003-12-18 | Glaxo Group Ltd., Greenford | Pharmazeutische aerosolformulierung |
| DE10056104A1 (de) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
-
2002
- 2002-09-06 WO PCT/EP2002/009974 patent/WO2003024452A1/de not_active Ceased
- 2002-09-06 JP JP2003528548A patent/JP2005504076A/ja active Pending
- 2002-09-06 EP EP02777013.0A patent/EP1429768B1/de not_active Expired - Lifetime
- 2002-09-06 MX MXPA04002401A patent/MXPA04002401A/es active IP Right Grant
- 2002-09-06 CA CA2459493A patent/CA2459493C/en not_active Expired - Fee Related
- 2002-09-12 UY UY27445A patent/UY27445A1/es not_active Application Discontinuation
- 2002-09-12 PE PE2002000899A patent/PE20030646A1/es not_active Application Discontinuation
- 2002-09-13 AR ARP020103470A patent/AR036518A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR036518A1 (es) | 2004-09-15 |
| EP1429768A1 (de) | 2004-06-23 |
| WO2003024452A1 (de) | 2003-03-27 |
| JP2005504076A (ja) | 2005-02-10 |
| CA2459493A1 (en) | 2003-03-27 |
| EP1429768B1 (de) | 2016-11-16 |
| CA2459493C (en) | 2011-08-02 |
| UY27445A1 (es) | 2003-04-30 |
| MXPA04002401A (es) | 2004-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2270806T3 (es) | Combinaciones de formoterol y de una sal de tiotropio. | |
| ES2572973T3 (es) | Composiciones que contienen formoterol y un esteroide para administración a los pulmones | |
| CR6937A (es) | Nuevo polvo inhalable conteniendo tiotropium | |
| CA2225601C (en) | New stable pharmaceutical preparation for producing propellant-free aerosols | |
| ES2687751T3 (es) | Tratamiento de enfermedades respiratorias | |
| ES2391563T5 (es) | Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor | |
| ES2195408T5 (es) | Procedimiento de formación de polvo que comprende micropartículas perforadas. | |
| US8367734B1 (en) | Stable epinephrine suspension formulation with high inhalation delivery efficiency | |
| TNSN04149A1 (en) | Pressurised metered dose inhalers containing solutions of beta-2 agonists | |
| RU2001126347A (ru) | Композиции, включающие формотерол и фуроат мометасона, предназначенные для лечения астмы | |
| ES2628891T3 (es) | Formulación farmacéutica que comprende un inhibidor de fosfodiesterasa | |
| JP2002538110A5 (es) | ||
| AR075516A1 (es) | Composicion farmaceutica para inhalacion | |
| CL2004001170A1 (es) | Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v | |
| PE20010133A1 (es) | NUEVAS COMPOSICIONES DE MEDICAMENTOS A BASE DE COMPUESTOS ANTICOLINERGICAMENTE ACTIVOS Y ß-MIMETICOS | |
| MX9700034A (es) | Formulacion para la aplicacion por inhalacion. | |
| NZ236974A (en) | Propellant gases comprising heptafluoropropane; use in pharmaceutical compositions | |
| JP2007536311A5 (es) | ||
| CA2550841A1 (en) | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases | |
| ECSP055855A (es) | Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato | |
| EP1915129A2 (en) | Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation | |
| PE20030646A1 (es) | Medicamentos para la inhalacion que comprenden sales de tiotropio y salmeterol | |
| EA201401354A1 (ru) | Новая дозированная форма и препарат, содержащий абедитерол | |
| DE4230876A1 (de) | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten | |
| BR0306663A (pt) | Formulação de salmeterol superfino |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |